Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $10.00 Price Target at HC Wainwright

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its target price decreased by HC Wainwright from $20.00 to $10.00 in a report published on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other equities research analysts have also commented on ZNTL. Wedbush reiterated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. UBS Group lowered their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday. Finally, Guggenheim dropped their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $8.58.

Zentalis Pharmaceuticals Stock Performance

ZNTL stock opened at $1.89 on Wednesday. The company’s 50 day moving average is $3.00 and its 200 day moving average is $3.30. Zentalis Pharmaceuticals has a 1-year low of $1.76 and a 1-year high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. Research analysts forecast that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current fiscal year.

Institutional Trading of Zentalis Pharmaceuticals

Several large investors have recently modified their holdings of ZNTL. Erste Asset Management GmbH bought a new stake in Zentalis Pharmaceuticals during the third quarter valued at approximately $37,000. Paloma Partners Management Co purchased a new position in shares of Zentalis Pharmaceuticals in the third quarter worth $37,000. Aigen Investment Management LP bought a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at about $41,000. Capstone Investment Advisors LLC purchased a new position in Zentalis Pharmaceuticals during the 3rd quarter valued at approximately $48,000. Finally, China Universal Asset Management Co. Ltd. increased its position in Zentalis Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after purchasing an additional 5,333 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.